Anthony Barron is presenting on “Quantifying the benefits of personalised medicines to patients, society and healthcare systems.” Charles River Associates has conducted an evidencebased analysis on behalf of The European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Biopharmaceutical Enterprises (EBE), to characterise and quantify the benefits of personalised medicines to patients, society and healthcare systems. This study seeks to identify barriers and enablers to the development and adoption of PM in Europe and elaborate strategic recommendations for decisionmakers to overcome these barriers and incentivise the development and adoption of PM in Europe.
For more information on this event, click here.
Introduction to PDABs: How US states are addressing high-cost prescription drugs
An in-depth look at how PDABs function, their influence across different states, and the latest updates from Colorado, Maryland, Washington, and Oregon.